CoChat

Managing haematology and oncology patients during the COVID ‐19 pandemic: interim consensus guidance

Open access
Weinkove, Robert, McQuilten, Zoe K, Adler, Jonathan, Agar, Meera R, Blyth, Emily, Cheng, Allen C, Conyers, Rachel, Haeusler, Gabrielle M, Hardie, Claire, Jackson, Christopher, Lane, Steven W, Middlemiss, Tom, Mollee, Peter, Mulligan, Stephen P, Ritchie, David, Ruka, Myra, Solomon, Benjamin, Szer, Jeffrey, Thursky, Karin A, Wood, Erica M, Worth, Leon J, Yong, Michelle K, Slavin, Monica A, Teh, Benjamin W · 2020 · Medical Journal of Australia
Cited by 123

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

INTRODUCTION: A pandemic coronavirus, SARS-CoV-2, causes COVID-19, a potentially life-threatening respiratory disease. Patients with cancer may have compromised immunity due to their malignancy and/or treatment, and may be at elevated risk of severe COVID-19. Community transmission of COVID-19 could overwhelm health care services, compromising delivery of cancer care. This interim consensus guidance provides advice for clinicians managing patients with cancer during the pandemic. MAIN RECOMMENDATIONS: During the COVID-19 pandemic: In patients with cancer with fever and/or respiratory symptoms, consider causes in addition to COVID-19, including other infections and therapy-related pneumonitis. For suspected or confirmed COVID-19, discuss temporary cessation of cancer therapy with a relevant specialist. Provide information on COVID-19 for patients and carers. Adopt measures within cancer centres to reduce risk of nosocomial SARS-CoV-2 acquisition; support population-wide social distancing; reduce demand on acute services; ensure adequate staffing; and provide culturally safe care. Measures should be equitable, transparent and proportionate to the COVID-19 threat. Consider the risks and benefits of modifying cancer therapies due to COVID-19. Communicate treatment modifications, and review once health service capacity allows. Consider potential impacts of COVID-19 on the blood supply and availability of stem cell donors. Discuss and document goals of care, and involve palliative care services in contingency planning. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT: This interim consensus guidance provides a framework for clinicians managing patients with cancer during the COVID-19 pandemic. In view of the rapidly changing situation, clinicians must also monitor national, state, local and institutional policies, which will take precedence. ENDORSED BY: Australasian Leukaemia and Lymphoma Group; Australasian Lung Cancer Trials Group; Australian and New Zealand Children's Haematology/Oncology Group; Australia and New Zealand Society of Palliative Medicine; Australasian Society for Infectious Diseases; Bone Marrow Transplantation Society of Australia and New Zealand; Cancer Council Australia; Cancer Nurses Society of Australia; Cancer Society of New Zealand; Clinical Oncology Society of Australia; Haematology Society of Australia and New Zealand; National Centre for Infections in Cancer; New Zealand Cancer Control Agency; New Zealand Society for Oncology; and Palliative Care Australia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5694/mja2.50607

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 50

  1. 10.1001/jama.2020.2648 · DOI · Paper page
  2. 10.1093/cid/cis844 · DOI · Paper page
  3. 10.1001/jama.2020.1585 · DOI · Paper page
  4. 10.1016/S1470-2045(20)30096-6 · DOI · Paper page
  5. 10.1016/S1470-2045(20)30150-9 · DOI · Paper page
  6. 10.1016/S1470-2045(20)30149-2 · DOI · Paper page
  7. 10.1038/s41409-018-0386-z · DOI
  8. 10.1056/NEJMoa2002032 · DOI · Paper page
  9. 10.1016/S0140-6736(20)30183-5 · DOI · Paper page
  10. 10.1016/S0140-6736(20)30566-3 · DOI · Paper page
  11. 10.1007/s00247-020-04656-7 · DOI · Paper page
  12. 10.1016/S0924-8579(00)00241-7 · doi:10.1016/s0924-8579(00)00241-7
  13. 10.1097/INF.0000000000002660 · DOI · Paper page
  14. 10.1016/S0140-6736(20)30154-9 · DOI · Paper page
  15. Chen Z, 2020, COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report, Zhonghua Xue Ye Xue Za Zhi, 41, E004
  16. 10.1371/journal.pone.0170774 · DOI
  17. 10.1001/jama.2020.3204 · DOI · Paper page
  18. 10.1016/S1470-2045(20)30096-6 · DOI · Paper page
  19. 10.1093/jpids/pix093 · DOI · Paper page
  20. 10.1016/S0002-9343(97)00003-X · DOI · Paper page
  21. 10.1016/j.jcv.2015.04.012 · doi:10.1016/j.jcv.2015.04.012
  22. Cancer Australia, Optimal care pathway for Aboriginal and Torres Strait Islander people with cancer
  23. Medical Council of New Zealand, 2019, Statement on cultural competence and the provision of culturally-safe care
  24. 10.1001/jama.2020.4031 · DOI · Paper page
  25. Medical Council of New Zealand, 2018, Safe practice in an environment of resource limitation
  26. Australian Government Department of Health, 2020, Australian health sector emergency response plan for novel coronavirus (COVID-19)
  27. 10.1186/s12885-016-2781-4 · DOI
  28. 10.1016/S1470-2045(08)70150-5 · DOI · Paper page
  29. 10.1097/01.inf.0000254148.09831.7f · DOI
  30. 10.1111/trf.14370 · DOI
  31. 10.1016/j.tmrv.2020.02.003 · DOI · Paper page
  32. World Health Organization, 2019, Protecting the blood supply during infectious disease outbreaks. guidance for national blood services
  33. 10.1001/jama.2019.0554 · DOI · Paper page
  34. 10.1111/imj.13434 · doi:10.1111/imj.13434
  35. 10.1111/bjh.16347 · DOI
  36. Carson JL, 2016, Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion, Cochrane Database Syst Rev, CD002042
  37. 10.1136/bmj.i1351 · DOI · Paper page
  38. 10.1056/NEJMoa1212772 · DOI · Paper page
  39. 10.1111/bjh.14423 · DOI · Paper page
  40. Estcourt LJ, 2019, The TREATT Trial (TRial to EvaluAte Tranexamic acid therapy in Thrombocytopenia): safety and efficacy of tranexamic acid in patients with haematological malignancies with severe thrombocytopenia: study protocol for a double-blind randomised controlled trial, Trials, 20, 592, 10.1186/s13063-019-3663-2 · doi:10.1186/s13063-019-3663-2
  41. 10.1093/cid/civ272 · DOI
  42. 10.1182/blood-2013-12-541359 · doi:10.1182/blood-2013-12-541359
  43. 10.1016/j.bbmt.2015.11.015 · DOI
  44. Australasian Bone Marrow Transplant Recipient Registry, 2018, Annual data summary 2018
  45. 10.1038/s41409-020-0873-x · doi:10.1038/s41409-020-0873-x
  46. 10.1016/j.ctro.2020.03.009 · DOI · Paper page
  47. 10.1046/j.0004-8461.2003.01165.x · DOI
  48. Therapeutic Goods Administration, 2018, ICH guideline for good clinical practice
  49. 10.1016/j.jpainsymman.2009.11.241 · DOI · Paper page
  50. 10.1191/0269216304pm859oa · DOI · Paper page

Cited by

See all 123

Metadata

Authors
Weinkove, R., McQuilten, Z. K., Adler, J., Agar, M. R., Blyth, E., Cheng, A. C., Conyers, R., Haeusler, G. M., Hardie, C., Jackson, C., Lane, S. W., Middlemiss, T., Mollee, P., Mulligan, S. P., Ritchie, D., Ruka, M., Solomon, B., Szer, J., Thursky, K. A., Wood, E. M., Worth, L. J., Yong, M. K., Slavin, M. A., & Teh, B. W.
Venue
Medical Journal of Australia
Publisher
Wiley
Published
2020-05-13
Volume
212
Issue
10
Pages
481-489
ISSN
  • 0025-729X (ISSN-L)
  • 1326-5377
OpenAlex
W3012421643
Cited by
123
References
2
FWCI
9.38
Type
journal article
Language
en
Open access
bronze
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Managing haematology and oncology patients during the COVID ‐19 pandemic: interim consensus guidance. https://app.cochat.ai/papers/10.5694/mja2.50607
The paper
Weinkove, R., McQuilten, Z. K., Adler, J., Agar, M. R., Blyth, E., Cheng, A. C., Conyers, R., Haeusler, G. M., Hardie, C., Jackson, C., Lane, S. W., Middlemiss, T., Mollee, P., Mulligan, S. P., Ritchie, D., Ruka, M., Solomon, B., Szer, J., Thursky, K. A., . . . Teh, B. W. (2020). Managing haematology and oncology patients during the COVID ‐19 pandemic: interim consensus guidance. Medical Journal of Australia. https://doi.org/10.5694/mja2.50607

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.